通过在温和条件下使用氢化硅烷和烯丙基硅烷完成了 InI 3 催化的酯的氢化烯丙基化。许多重要的基团,如链烯基、炔基、氰基和硝基基团在这些条件下仍然存在。该反应体系为高烯丙醇和醚提供了途径,其中烷氧基部分或羰基氧原子的消除可以通过改变烷氧基部分和氢硅烷上的取代基自由选择。此外,内酯的氢烯丙基化发生在不开环的情况下,以高产率生产所需的环醚。
[UO2(OTf)2] reduces a series of aromatic and aliphatic aldehydes and ketones into their corresponding alcohols with moderate to excellent yields, using iPrOH as a solvent and a reductant. The reaction proceeds under mild conditions (80 °C) with an optimized catalytic charge of 2.3 mol % and KOiPr as a cocatalyst. The reduction of aldehydes (1–10 h) is faster than that of ketones (>15 h). NMR investigations
Method and compositions for identifying anti-HIV therapeutic compounds
申请人:Arimilli N. Murty
公开号:US20050239054A1
公开(公告)日:2005-10-27
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
[EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER AVEC LESDITS COMPOSÉS
申请人:UNIV HEALTH NETWORK
公开号:WO2013053051A1
公开(公告)日:2013-04-18
The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.
The present invention relates to a compound represented by formula (I): wherein R
1
represents a hydrogen atom or the like; R
2
and R
3
represent a hydrogen atom or the like; R
4
is a group represented by (II) R
5
represents a phenyl group which may be substituted with a halogen or the like; m is an integer of from 1 to 3; and p is an integer of from 0 to 4; or a pharmaceutically acceptable salt thereof.
A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by following formula (I):
wherein R
1
and R
2
represent hydrogen atom, or the like; R
3
represents an alkyl group containing 1 to 6 carbon atoms, or the like; R
4
and R
5
independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like, with the proviso that R
4
and R
5
do not simultaneously represent hydrogen atom; or the substituents R
4
and R
5
together represent (a) a 3- to 6-membered cyclic structure including the carbon atom shared by R
4
and R
5
to form a spirocyclic structure with the pyrrolidine ring; R
6
and R
7
independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like; R
8
represents a halogen-substituted alkyl group containing 1 to 6 carbon atoms, or the like; X
1
represents hydrogen atom or a halogen atom; A represents nitrogen atom or a moiety represented by formula (II):